Tumor-infiltrating lymphocytes (TILs) include CD8+ T cells and CD4+ T cells, for example, are unique independent prognostic markers for UVM patients and play essential roles in tumor recurrence, metastasis, dissemination, and responsiveness to immunotherapy (33–35). This evidence concerns the gene CD8A and neoplasm.